Owlstone Medical secures investment from Cystic Fibrosis Foundation
Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced ...
Tag: Precision Medicine
EZH2 inhibition offers hope for fighting treatment-resistant cancers
The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review ...
A step toward precision medicine: New drug targets for heart failure
A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its subtypes, offering new ...
Mapping human biology: Human Cell Atlas leads a new era in precision medicine
From cells to solutions: The Human Cell Atlas pioneers a global effort to map human biology and bridge health inequities ...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy
In this interview from SfN 2024, Professor Nancy Ip, President of The Hong Kong University of Science and Technology, shares ...
AI model could help clinicians to understand prostate tumor's aggressiveness
Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year ...
AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib)
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the ...
PlaqueTec closes $8 million equity financing
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has secured $8 ...
Largest study of BRCA1 and BRCA2 carriers refines cancer risk estimates in Asian population
A team of clinician-scientists and scientists from the University of Nottingham (Malaysia campus), National Cancer Centre Singapore (NCCS), Cancer Research Malaysia, ...
BGI Genomics enhances NIFTY prenatal testing kit with DNBSEQ-G99 platform for faster and accurate results
BGI Europe A/S, a wholly owned subsidiary of BGI Genomics, announced its NIFTY® non-invasive prenatal testing kit and software (CE-IVDD ...